Activating the receptor of THC, which is the cannabinoid receptor (CBR), results in the removal of Aβ deposits in vitro [10] and, in vivo, improves tau and amyloid pathology in a mouse model of tauopathy [11], affects the oxidative stress response in an APP/PS1 mice model of AD, and reduces cognitive deficits in mouse and rat AD models [12,13,14,15]. This evidence concerns the gene MAPT and Alzheimer disease.